A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer

Inclusion Criteria: * Adult patients, aged ≥18 years; * Histologically confirmed advanced or metastatic adenocarcinoma of gastric cancer(AGC) , including adenocarcinoma of the gastroesophageal junction ; * At least one measurable and evaluable disease based on response evaluation criteria in solid tumors (RECIST v1.1); * Patients must have received one prior chemotherapy regimen for AGC;First-line therapy must have included a combination of at least a platinum-based treatment given concurrently, and must have experienced disease progression during or after first-line therapy for their disease; * Eastern Cooperative Oncology Group(ECOG) performance status of 0 or 1; * Life expectancy of more than 3 months; * Duration from the last therapy is more than 6 weeks for nitroso or mitomycin, More than 4 weeks for other cytotoxic agents, operation or radiotherapy; * Adequate hepatic, renal, heart, and hematologic functions ( hemoglobin≥ 90g/L, platelets ≥ 80 × 109/L, neutrophil ≥1.5 × 109/L, serum creatinine≤ 1.5mg/dl, total bilirubin ≤1.5 ×ULN, and serum transaminase≤2.5×ULN); Exclusion Criteria: * Pregnant or lactating women; * History of other malignancies except cured basal cell carcinoma of skin and carcinoma insitu of uterine cervix; * Prior chemotherapy regimen have included taxane (docetaxel or paclitaxel); Uncontrolled hypertension; * Intercurrence with one of the following: coronary artery disease, arrhythmia and heart failure; * Urine protein\>grade 1; * Any factors that influence the usage of oral administration; * patients with a clear tendency of gastrointestinal bleeding; * Abnormal coagulation function(INR≥1.5, APTT≥1.5 ULN); * Abuse of alcohol or drugs; * Less than 4 weeks from the last clinical trial; * Prior treatment with antivascular endothelial growth factor or the other anti angiogenesis therapy; * Evidence of central nervous system(CNS) metastasis; * Disability of serious uncontrolled intercurrence infection.